J&J poised for growth despite reg concerns; Medtronic funds MC10's stretchable electronics;

 @FierceMedDev: Malaysia is working hard to diversify its med device manufacturing base. International competition is increasing. News | Follow @FierceMedDev

@MarkHFierce: Barron's sees J&J poised for major growth, but NOT through its med device business. More | Follow @MarkHFierce

 @DamianFierce: Quintiles is handling recruitment and "clinical services" for AstraZeneca's novel depression drug. Story | Follow @DamianFierce

> Despite regulatory concerns and the ire of Warren Buffett, Johnson & Johnson ($JNJ) may still be poised for growth, Barron's writes. Article

> ConvaTec has made the leap to India, opening a headquarters in Bangalore, looking to cash in on the country's fast-growing market for medical devices and equipment. More

> Abbott Laboratories ($ABT) got FDA clearance for a new testosterone diagnostic assay the company says can measure the hormone at low levels, helping guide treatment. Release

> Qiagen gained approval from China's State Food and Drug Administration for its careHPV test and instrument platform. Item

> VC outfit Apple Tree Partners has struck a $305 million licensing deal designed to raise funds to build up a collection of biotech and medical device companies. News

> Andrew Technologies snagged 510(k) clearance for its HydraSolve lipoplasty system. Item

> Dominion Diagnostics inked an exclusive deal with LifeGen for licensing rights to patented genetic testing. Release

> MC10, a Cambridge, MA, developer of stretchable electronics raised $10 million in a Series C, led by Medtronic ($MDT). Story

Biotech News

 @FierceBiotech: Baxter joins Big Pharma funds on $38M B round for Naurex anti-depression R&D. Article | Follow @FierceBiotech

@JohnCFierce: Troubled Intercell (bought Iomai) throws in the towel, signs off on merger deal with Vivalis. More | Follow @JohnCFierce

@RyanMFierce: Dang. Another biotech deal this busy am. Naurex nails down $38M B round led by Baxter for depression candidate. Release | Follow @RyanMFierce

> Tranzyme takes a beating after scuttling another drug study. Report

> Apple Tree inks $305M drug deal to back biotech portfolio game plan. News

> Phenex grabs $135M discovery deal with J&J. Item

Pharma News

@FiercePharma: AstraZeneca beats back would-be Crestor copycats. Report | Follow @FiercePharma

> France herds patients, pharmacists toward cheap generics. News

> Teva taps S. Korea's Handok for assault on $14B market. Story

> U.S. branded sales to end 2012 with 3.5% decline. Article

Biotech IT News

> How lessons from iPhone's Siri aid biological exploration. Story

> GlaxoSmithKline dials up Vodafone for mobile tech alliance. Article

> Russian billionaire backs 23andMe in $50M round. News

> Could computers predict the next big Alzheimer's drug? Report

CRO News

> Patheon closes $255M Banner deal. Item

> Charles River projects a modest 2013, slides on the Street. Story

> Catalent inks biosimilar deal with Japanese CMO. Article

> Quintiles recruiting for AstraZeneca's novel depression drug. News

> Warnex closes bioanalytics sale, exits CRO biz. Report

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.